Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 10 of 10 descriptions
No. | Drug (Description in trials) | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | Disease ID | ||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Dalfampridine | [1] Dalfampridine Dalfampridine | [1] Dalfampridine
Dalfampridine
💬1. Dalfampridine
| [4] KCNA4 KCNA4,KCNC3, KCND2, KCND3 💬 | [4] Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 [4] Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia ... | [2] 4 4, 13 💬
| ||||||||||||||||||||||||||||||||||
2 | Daraprim | [1] Pyrimethamine Pyrimethamine | [1] Pyrimethamine
Pyrimethamine
💬2. Daraprim
| - | - | [2] 2 2, 4 💬
| ||||||||||||||||||||||||||||||||||
3 | Dexdor | [1] Dexmedetomidine Dexmedetomidine | [1] Dexmedetomidine
Dexmedetomidine
💬3. Dexdor
| [3] ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | [4] 2 2, 4, 6, 70 💬
| ||||||||||||||||||||||||||||||||||
4 | DEXMEDETOMIDINE | [1] Dexmedetomidine Dexmedetomidine | [1] Dexmedetomidine
Dexmedetomidine
💬4. DEXMEDETOMIDINE
| [3] ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | [14] 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬4. DEXMEDETOMIDINE
| ||||||||||||||||||||||||||||||||||
5 | ESKETAMINE | [1] Esketamine Esketamine | [1] Esketamine
Esketamine
💬5. ESKETAMINE
| [5] GRIN1 GRIN1,GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 5. ESKETAMINE | [20] Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 [20] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium si ... | [3] 2 2, 4, 70 💬
| ||||||||||||||||||||||||||||||||||
6 | Ketanest | - | - | - | - | [3] 2 2, 4, 70 💬
| ||||||||||||||||||||||||||||||||||
7 | Ketanest-S | - | - | - | - | [3] 2 2, 4, 70 💬
| ||||||||||||||||||||||||||||||||||
8 | Levetiracetam | [1] Levetiracetam Levetiracetam | [1] Levetiracetam
Levetiracetam
💬8. Levetiracetam
| [1] SV2A SV2A 💬8. Levetiracetam
| [1] ECM-receptor interaction ECM-receptor interaction 💬 | [5] 2 2, 4, 6, 13, 307 💬
| ||||||||||||||||||||||||||||||||||
9 | PYRIMETHAMINE | [1] Pyrimethamine Pyrimethamine | [1] Pyrimethamine
Pyrimethamine
💬9. PYRIMETHAMINE
| - | - | [4] 2 2, 4, 19, 65 💬
| ||||||||||||||||||||||||||||||||||
10 | Stem Cells | - | - | - | - | [5] 2 2, 4, 46, 96, 113 💬
|